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Abstract  
 
Background: The need to consider sustainable healthcare solutions is essential. An innovative 
strategy used to promote minor ailment care is the utilisation of community pharmacists to deliver 
minor ailment services (MASs). Promoting higher levels of self-care can potentially reduce the strain 
on existing resources. 
 
Aim: To explore the features of international MASs, including their similarities and differences, and 
consider the essential elements to design a MAS model. 
 
Methods: A grey literature search strategy was completed in June 2017 to comply with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses standard. This included (1) 
Google/Yahoo! search engines, (2) targeted websites, and (3) contact with commissioning 
organisations. Executive summaries, table of contents and title pages of documents were reviewed. 
Key characteristics of MASs were extracted and a MAS model was developed.    
 
Results: A total of 147 publications were included in the review. Key service elements identified 
included eligibility, accessibility, staff involvement, reimbursement systems. Several factors need to 
be considered when designing a MAS model; including contextualisation of MAS to the market. 
Stakeholder engagement, service planning, governance, implementation and review have emerged 
as key aspects involved with a design model. 
 
Conclusion: MASs differ in their structural parameters. Consideration of these parameters is 
necessary when devising MAS aims and assessing outcomes to promote sustainability and success of 
the service.  
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Classification and keywords 
 
Keywords 
Minor ailments, Minor ailments services, Minor conditions, Self-care, Community pharmacy, 
Community pharmacy services 
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3 
A review of international pharmacy-based minor ailment services and proposed service design 
model 
Introduction 
Self-care is a key facet of primary health care 1 and a key public health resource 2 pervading all types 
of public health and medical care. 3 The World Health Organisation (WHO) defines self-care as “the 
ability of individuals, families and communities to promote health, prevent disease, maintain health 
and to cope with illness and disability with or without the support of a health-care provider”.1 The 
emphasis on self-care has been accentuated by the WHO and international government policies. 2-9 
It is well recognised that self-care delivers resource optimisation, limits health expenditures, 
increases patient satisfaction, improves healthcare and disease outcomes, and improves quality of 
life. 10-14 It empowers an individual to take accountability for their conditions to achieve health care 
solutions, which is facilitated by increased access to medicines, remedies and information. 15 Self-
care is often the preferred treatment option to manage minor ailments. 13 Minor ailment treatment 
and self-medication with over-the-counter (OTC) products are considered ‘the traditional heartland 
of self-care’.16 Furthermore, self-care is considered to be of increasing importance in the 
management of certain minor ailments 17 and plays a crucial role to deliver resource optimisation, 
limit health expenditure, empower individuals, increase patient satisfaction and improve healthcare. 
10, 13, 14 
Community pharmacists play a key role in promoting self-care, 13, 18, 19 and are ideally placed to 
promote consumer self-care and self-medication. 20 They are trusted, accessible health care 
professionals that already deliver sustainable healthcare solutions. 21-23 An innovative strategy used 
to promote access to minor ailment care is the utilisation of community pharmacy and pharmacists 
to deliver minor ailment services (MASs) in collaboration with patients. The emergence of MASs are 
incorporated into government policy to increase the accessibility to primary health care, reduce the 
demand for minor ailment care at accident & emergency (A&E) and general practitioner (GP) 
services, improve resource allocation, and promote a better quality of patient care. 24  The increased 
utilisation of community pharmacy-based minor ailment care is driven by many factors: including the 
rising pressures on A&E 25-29 and GP services 4, 30, 31; high volumes of A&E and GP presentations and 
extended waiting times to access appropriate medical care. This influences individual’s access to 
timely care. The need to consider cost effective, sustainable healthcare solutions is multifaceted; 
driven by ageing populations, a mounting burden of chronic disease and continuing economic 
pressure on health care systems. 32-36 
MASs exist nationally in Scotland, 37 Northern Ireland, 38 parts of Wales, 39 parts of England, 40 and 
parts of Canada. 41 They are on, or attempted to be included in the policy agenda in a number of 
other countries and regions, including Australia, 21, 42 New Zealand 43, 44 and Ontario (Canada). 45 
These programs allow pharmacists to provide essential primary care services in a structured manner; 
offering advice, treatment and/or referral if necessary 14, 23, 46, 47 and allow greater access to health 
services, greater workforce utilisation, with increased emphasis on self-care. 5, 48, 49  
A systematic review published in 2013 suggests that MASs are associated with positive patient 
outcomes and economic benefits. 50 GP re-consultation rates following MAS consultation vary from 
2.4-23.4%, and high levels of symptom resolution are reported following initial MAS consultation, 
68-94%. 50 MASs reduce GP’s minor ailment workload by 1.4-56.6%, 50 produce positive health 
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outcomes 50-52 and are associated with positive stakeholder views. 24, 50, 52-54 In the UK, pharmacy- 
based care of minor ailments was more cost-effective than other higher cost settings, 55, 56 highest in 
A&E £147.09 compared with £82.34 and £29.30 in GP and pharmacy- based settings, respectively. 55 
Similarly, Rafferty et. al presented similar findings regarding the cost-effectiveness of pharmacy-
based minor ailment care in Saskatchewan, Canada. Community pharmacy offered the most cost-
effective treatment site of $18 CAD, whereas the cost of a GP exploratory appointment and A&E 
visits were estimated at $66.40 CAD and $138 CAD. 57  
International MASs are characterised by different structural features and service delivery, and 
operationally vary from an organisational and management perspective. However, all schemes 
appear to be based on similar principles and standards. At present, no MAS model exists to aid the 
design of the service, despite the clear benefits to effective MAS implementation in community 
pharmacy. A MAS model presents a structured framework to guide the organisation and 
development of a MAS for service providers to deliver high levels of service delivery, integration and 
support into the primary care arena.   
Study Objective 
The objective of this systematic review was to identify the elements and features associated with 
pharmacy- based MASs in order to facilitate the design and implementation of a standardised MAS 
model.  
Methods 
A literature search was conducted in June 2017 according to the grey literature searching strategies 
outlined by Godin et al 58 to comply with the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) standard.  For the purposes of this review, the use of grey literature was 
necessary, as it contains relevant policy and research data, such as standards and guidelines from 
official, authoritative sources not normally published in the scientific literature. This provided the 
most accurate, detailed and recent information pertaining to current MAS structural elements. It 
offered specific process and planning information that was unavailable in scientific, peer-reviewed 
research materials. Published research material offered little information regarding the research 
aims, as they were evaluation documents, as opposed to service standards and guidelines.  
English literature associated with the service elements and implementation of community 
pharmacy-based MASs were included. No publication date filters were used. English language 
records including the protocols and standards for implementation of community pharmacy based 
MAS published by a government organisation, professional body or commissioning organisation 
were included in their most current, updated form. Records removed based on the exclusion criteria 
included those that were (1) not published in English language, (2) not published by a 
commissioning/professional organisation, (3) draft/ out dated documents, (4) not inclusive of a 
community pharmacy based MAS, or (5) not inclusive of MAS implementation standards.  
Information sources and search strategy 
The term “minor ailment service”(MAS) is recognised across UK-based literature as a structured 
community pharmacy-based service to assess, treat and manage minor ailments. However, the term 
“minor ailments assessment” and/or “minor ailments prescribing” is used in Canada to characterise 
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community pharmacist’s assessment and prescribing for minor ailment conditions. For the purpose 
of this review, the term MAS is used interchangeably for all regions and countries. 
The search strategy was developed to include three components: (1) Google and Yahoo! search 
engines, (2) targeted websites, and (3) contact with commissioning bodies and professional 
organisations to identify the countries/regions that operated pharmacy-based MASs and the 
relevant details. 
The first search strategy involved the application of 14 unique queries to Google and Yahoo! Search 
Engines listed in Table 1. Twenty results were selected for the initial five queries; however, no 
relevant data was located in the latter ten records. Consequently, ten results were selected for each 
search category. The first ten results of each search’s hits were reviewed by the title and 
accompanying text. Ten results for each search category were selected. Websites were bookmarked 
using a bookmark manager. For each search strategy utilised, the search terms and the number of 
results obtained were recorded and duplicate records were removed.  
Table 1: Search strategies used for literature retrieval 
The second search strategy involved a review of websites of professional groups and commissioning 
organisations with the search terms of “minor ailments scheme” OR “minor ailments assessment”. 
These search terms were selected as they yielded similar results to all other combinations (including 
“minor illness service,” “minor ailment prescribing service” etc.). Google and Yahoo! search engines 
were used to identify organisations of relevance to MASs and the relevant subject area. A list of the 
groups and organisations searched is documented in Appendix 1. The first ten results of each 
search’s hits were reviewed for relevant titles and information using the URL and the additional text 
below the title. The date and website’s URL was recorded. Each of the ten resulting websites were 
‘hand-searched’ for the relevant documents until the relevant information was found.  
The third search strategy was only used if none or minimal data were obtained from the previous 
two search strategies. Sixty-six individuals associated with commissioning bodies/professional 
organisations were contacted by email to obtain the relevant documents and obtain the necessary 
data. The introductory email introduced the research team, the scope of the research undertaken, 
and the potential information/documents requested and/or a request to forward the email to a 
colleague who would be more suitable to offer assistance.  
Eligibility assessment and data selection 
The literature selection process was undertaken and discussed between two authors, (KW and MA). 
To determine potentially relevant records, a screening of records retrieved from the search was 
performed. This process was over-inclusive. The title and source organisation or group of records 
were gathered and duplicate documents were excluded. The executive summaries, table of 
contents, and title pages of documents were reviewed to identify their relevance to research aims. 
The full-text documents of all items were obtained and reviewed. Documents that were considered 
irrelevant were excluded according to the exclusion criteria. All documents that remained after full 
text screening were included.  
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Data collection process and synthesis of results 
A pre-designed spreadsheet was produced to assist in data collection and management. Data 
collected included: the year of service commencement, service commissioner, eligible patient 
groups, location of service delivery, patient outcomes, healthcare professional collaboration, patient 
cost, number of minor ailments treated, number of drug formulary items, pharmacy reimbursement, 
pharmacy/staff accreditation, patient follow up and quality control.  
Results 
The search strategies generated 719 relevant items for screening (see Figure 1).  Five hundred and 
fifty-one records were excluded according to the exclusion criteria.  
Figure 1: Study flow diagram 
From these 147 records, twelve were from Canadian professional organisations, eight were from 
Scottish professional organisations, four were from Welsh organisations, and three were from 
Northern Irish organisations. The remaining 120 records were from English pharmacy organisations 
and Clinical Commissioning Groups (CCGs).  
Analysis of service specifications 
Service description 
A total of 94 MASs were identified internationally across 103 regions, areas or countries in UK 
(Scotland, Northern Ireland, England, Wales) and Canada as of the 1st June 2017. These services 
varied in their structural design. A single national MAS was identified in Scotland (n=1) and Northern 
Ireland (n=1).  
In England, Wales and Canada, MASs were operated locally/regionally. In Wales, a MAS operated in 
two health board areas (with the intention to roll out nationally).  In England, 83 MASs operate 
across 92 regions (three commissioning bodies offer the same service over multiple areas).  Of these 
English MASs, 26/83 (31%) MASs were commissioned by 11 Area Teams (ATs) and 57/83 MASs (68%) 
were commissioned by 64 Clinical Commissioning Groups (CCGs). ATs were responsible for 
healthcare commissioning and service delivery in the regional areas whereas CCGs were responsible 
for commissioning the majority of hospital and community National Health Services (NHS) services in 
the local area that they were accountable for. 
In Canada, 8/13 (61%) of provinces operated MASs commissioned by their respective provincial 
pharmacy organisations. MASs ranged in complexity and the main characteristics of the service 
specifications are summarised in Appendix 2.  
MAS characteristics 
Patient groups 
MASs were structured to meet the needs of several different patient groups. UK based MASs (n= 83) 
were available to individuals who were exempt from prescription charges. In England, 33/73 (45%) 
of MASs were offered exclusively to individuals exempt from prescription charges. Some MAS 
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7 
services were available to those that do pay prescription charges, 48/73 (65%). Several UK based 
MASs had additional criteria to access MASs, including local GP registration or age restrictions, etc.  
Canadian MASs (n=3) were available to all individuals who were residents of the provincial area. (No 
information regarding the remaining Canadian MASs was located). The MAS offered in 
Saskatchewan (Canada) differed slightly to other Canadian services, as the service was only available 
to patients that had the capacity to “self diagnose” their minor ailment. Thus, for individuals in 
Saskatchewan to access the local MAS they needed to clearly communicate the ailment that they 
were suffering from, instead of just seeking assessment or diagnosis of their minor ailment condition 
from the consulting community pharmacist. If a pharmacist could not confirm or agree with a 
patient’s self- diagnosis, the patient needed to be referred to their GPs.  
Accessibility 
The access to English, Scottish, and Northern Irish MASs was through a variety of pathways, 
including self-referral or GP Practice staff referral. To access 12/65 (18%) English MASs, MAS users 
needed either formal documentation or referrals from either a GP or GP Practice staff. This could be 
in the form of an access card, referral letter or “MAS passport”. In contrast, 53/65 (82%) English MAS 
were accessible without such referral or documentation. No information could be obtained about 
access methods to the Welsh or Canadian MAS.  
Service specifications 
All UK-based MASs required service providers to: 
• offer the patient advice, or  
• offer advice and a medicinal product from a specific, defined formulary accompanied by 
advice on its use, or  
• offer advice plus a referral to a more appropriate health care provider.  
 
English (n=83), Northern Irish (n=1) and Welsh (n=1) MASs did not require pharmacists or pharmacy 
staff to follow up the patient’s following initial consultation. In Scotland (n=1), patient follow up was 
at the discretion of the pharmacist.  
 
All Canadian MASs (n=5) offered a similar service specification to UK based MASs’ to offer advice, 
and/or medicinal product and/or referral. Medicinal products included over the counter (OTC) and 
prescription products (if deemed necessary), and pharmacists were permitted to initiate these 
prescriptions. According to the MAS guidelines for which detailed service specifications were 
available (3/8), in New Brunswick and Nova Scotia, this prescription could be presented at any 
community pharmacy in the province. Patients were at the liberty to obtain the prescribed 
medication at any community pharmacy of their choice. All Canadian MASs (n=5) stipulated the 
requirement for patients to be followed up after their initial pharmacist assessment and 
consultation. No information regarding the remaining Canadian MASs was located.  
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8 
Patient cost 
 
All UK-based MASs required service providers to deliver MAS at no cost to individuals who were 
exempt from prescription charges. (Prescription charges were abolished in Scotland, Northern 
Ireland and Wales.) 
 
English MASs 33/73 (45%) that were available to individuals that were not exempt from prescription 
charges (i.e. individuals who had to purchase prescriptions) required a patient to pay the 
prescription levy or purchase the OTC products (whichever is cheaper). No information was obtained 
regarding the patient cost to access MASs in Canada. This was determined by the cost of the item 
they required for minor ailment treatment.   
 
Staff involved in MAS provision 
 
English MASs were delivered by either pharmacists or trained pharmacy staff members. A total of 
37/72 (51%) of English MASs were operated exclusively by pharmacists and 35/72 (49%) of MASs 
were operated by pharmacists and/or pharmacy staff members. The Scottish, Northern Irish, and 
Welsh MASs were operated exclusively by pharmacists. All Canadian MASs (n=8) were operated 
exclusively by pharmacists. 
  
Privacy requirements 
A significant proportion of MASs required MAS consultations to be delivered in a private, 
confidential setting. All English (n=83), Northern Irish, Welsh and Canadian MASs (n=2) required 
consultations to be conducted in a private, confidential manner. The guidelines did not cover issues 
regarding the privacy of NHS Scotland MAS consultations.  
Minor ailments treated  
The variety of minor ailments treated by English based MAS varied from one to 47 minor ailments 
(n=73). The Scottish, Welsh and Northern Irish service specification treated 25, 10 and 28 minor 
ailments respectively.  The complexity of conditions varied across MASs. The most common 
indications across UK based MAS included vaginal thrush (52/70), hay fever (49/70) and, sore throat 
(48/70).   
A total of 13/73 (18%) of English MASs were associated with Patient Group Directions (PGDs) 
allowing pharmacists to treat presenting minor ailments with more complex products including 
antibiotics. A PGD is a locally enhanced NHS service where the pharmacy can supply or administer 
prescription-only medicines (POMs) under a PGD to patient groups.  
The variety of minor ailments treated by Canadian-based MAS varied from 12-34 minor ailments 
(n=6). Vaginal thrush, allergic rhinitis, haemorrhoids and canker sores were treated in 6/6 Canadian 
MASs.  
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Formulary 
Minor ailment conditions can be treated with the use of OTC or prescription medicines if considered 
appropriate and necessary. Each Scottish NHS Board region has developed a local MAS formulary in 
conjunction with local stakeholders. Pharmacists can supply all Pharmacy (P) & General Sale List 
(GSL) medicines that are not blacklisted, dressings and appliances from Part 2 of the Drug Tariff and 
selected items from Part 3 of the Drug Tariff. Certain POMs can be supplied if underpinned by a PGD. 
POMs available under Scottish PGDs include Chloramphenicol 0.5% eye drops and Fluconazole 
150mg capsules. 
In Northern Ireland and Wales, a uniform formulary exists with P and GSL items, consisting of 31 and 
60 items, respectively. In England, each CCG has developed their own local formulary in conjunction 
with local stakeholders consisting of P, GSL and POMs. The number of medicinal products supplied 
by the different CCGs varies from one to 97 items. Medicines available under English PGDs include 
the influenza vaccine and oral antivirals. Trimethoprim 200mg tablets was available in 12/13 (92%) 
MASs offering PGDs, whereas chloramphenicol 0.5% eye drops and fusidic acid 2% cream were 
available in 8/13 (61%) and 6/13 (46%) MASs offering PGDs. 
Similarly, a wide variety of medicinal items were supplied by Canadian MASs. The range of medicinal 
products supplied varied from 52- 84 items (n=2). The Saskatchewan formulary consisted of a range 
of Schedule I items (prescription drugs appropriate for pharmacists to prescribe under specific 
circumstances).  
Additional pharmacist training requirements 
 
Many MASs required pharmacists or appropriately trained staff members to complete additional 
training or competency assessments. In England, 33/69 (48%) of service commissioners required 
pharmacists or appropriate trained staff members to complete additional training. The training and 
pharmacist accreditation methods varied to include attendance at organised training events, 
completion of accredited minor ailments training material and relevant continuing professional 
development education.  However, 36/69 (52%) of service commissioners did not require 
pharmacists to complete any additional training requirements. Moreover, 3/69 (4%) of service 
commissioners required pharmacists or appropriately trained staff members to complete additional 
training for the supply of POMs, but did not require pharmacists or appropriately trained staff 
members to offer P or GSL Items.  
Similarly, pharmacists needed to complete mandatory training to offer the MAS in Scotland, whereas 
there were no compulsory training requirements for pharmacists to complete in Wales or Northern 
Ireland.  
However, 4/5 (80%) of Canadian MAS provincial commissioning organisations required pharmacists 
to complete additional training (No information regarding the remaining Canadian MAS was 
located). Most provinces offered online training courses.  
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Remuneration schedules 
 
The level of pharmacy reimbursement differed across programs. All UK-based MAS commissioners 
offered MAS contractors varied forms of reimbursement, whereas Saskatchewan and Alberta 
(Canada) were the only Canadian governments to offer reimbursement to pharmacists (of $18 
CAD/prescription and $25 CAD/assessment, respectively). No information regarding the remaining 
Canadian MASs was located.  
 
In England, 60/64 (94%) of service commissioners remunerated MAS service providers with a fee 
using a common payment model that involved setting a consultation fee and payment for drug costs 
including taxes. This consultation fee varied from £2.00- £10.00. In addition, 4/64 (<1%) of service 
commissioners offered a single fixed consultation fee only and 7/64 (11%) of service commissioners 
offered additional fees or payments for administrative/additional costs or retainer fees. The 
capitation model, which sets a rate on a per-patient scale, was less commonly used in England by 
2/64 (3%) of service commissioners. This capitation model was used by commissioning bodies in 
Scotland, Wales and Northern Ireland.  
 
A table summarising the key elements and characteristics of MASs can be found in Appendix 2.  
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Proposed service design model 
The increasing uptake of international MASs is encouraging as it reduces the burden of care at other 
primary care sites, and demonstrates patient acceptability and adoption of increased utilisation of 
pharmacists as primary care providers. Evidence indicates that individuals prefer self-care and 
community pharmacy is the preferred source of advice. 13, 59 Furthermore, individuals are seeking 
health care solutions from a greater variety of sources including community pharmacies, social 
networking sites and the internet, particularly as successful health systems allow individuals to take 
responsibility for their own minor ailments. The increased utilisation of self-care and non-
prescription medication to treat minor ailments enhances individual’s confidence to manage their 
own health and well-being. 12  
As the demand for self-care increases and policymakers highlight the role of the shared 
responsibility in health care, 21, 23, 40, 42 the importance of integrated self-care models into the primary 
care domain is essential. Effective implementation of such models is profoundly important to ensure 
their viability and sustainability, and potential scale-up of services. 
Concepts have emerged across the multiple service standards reviewed consisting of a series of 
elements for consideration. Several factors need to be considered for the implementation of a MAS 
particularly the contextualisation of the service for the market, the role of GPs at the centre of 
patient primary care management, and needs of the population. Successful development and 
implementation of a local MAS requires an understanding of the way the new intervention will affect 
the health workforce, health consumers, medical practitioners and the overall health care system. 
Successful MAS implementation and utilisation requires use of multiple strategies including the use 
implementation and change management theories. 
The implementation of an MAS is a multi-stage, collaborative process with significant stakeholder 
impacts. Effective development and implementation of the program into pilot sites is essential to 
establish if wider utilisation is warranted. An initial needs assessment of the area or locality is 
essential to understand population data and demographics, existing primary care service utilisation 
and existing providers. Using this data, an estimate of MAS utilisation can be derived and MAS model 
elements can be considered. A proposed service design model has been presented to describe the 
implementation process, using a collaborative method (Figure 2).  
Figure 2: Proposed service design model  
Stakeholder engagement 
Key collaborators regarding MAS design include representatives of consumers, GPs, pharmacists, 
and policy makers. The involvement of stakeholder groups is critical throughout such an iterative 
process to identify and recognise the impact of changes in the health care system. It is proposed that 
stakeholders would be actively participants in the conceptualisation, creation, development, 
implementation, evaluation, quality control and improvement of the service. 
Service planning and design 
Service planning and design is critical and requires detailed service protocols to aid staff and 
stakeholders associated with the MAS. The protocol should encompass any mandatory, regulatory 
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requirements as well as physical resources, and changes to the staff workflow.  Effective MAS 
implementation entails the use of a robust framework. Collaborative agreements on protocols and 
referral pathways would need to be developed. It is important to note that in many countries, the 
population already uses community pharmacy as a source of minor health treatment advice. 
However, there are no formal pathways for referral or protocols agreed with other stakeholders 
such as A&Es and consumers. 
Establishing a governance structure 
A multi-level governance structure could be established to lead, plan and implement the MAS, with 
clearly defined lines of reporting and accountability. The multi-level governance structure could be 
composed of various members representing the stakeholder groups and an implementation team 
could report to the main governance committee. 
Implementation 
Community pharmacies in at least two pilot regions, using a randomised clustered control trial 
methodology are to implement the MAS for six months. Pharmacists are to be educated on minor 
ailments, their treatment, and referral protocols. Treatment protocols to be agreed with GPs, 
ensuring an integrated and collaborative model. Patient details, nature of consultation, referral and 
re-consultation rates, changes in GP workload, and treatment offered to be collected. Baseline data 
on the use of A&E and GPs’ minor ailment workload to be used as the control. 
Monitoring, review and evaluation 
An extensive objective and systematic evaluation of the MAS operating from pilot sites will need to 
be completed before wide-scale implementation is considered to determine if the service is 
achieving intended outcomes. The evaluation could comprise of an assessment of both process and 
outcome indicators that will consider the effectiveness, efficiency, relevance, impact and 
sustainability of the program. Clinical, economic and humanistic impact data could be analysed using 
time series analysis. Patient details, nature of consultation, referral, and re-consultation rates and 
treatment offered could also be collected.  
Discussion 
MASs led by community pharmacists aim to release primary care capacities by managing minor 
ailments through self-care and treatment available in community pharmacies. The underlying 
objectives of an MAS, as defined the UK and Canadian schemes, is to improve health outcomes, 
actively promote self-care and treat individuals suffering from minor ailments promptly. They 
endeavour to reduce overall health care expenditure indicated by national government policies. 37, 39-
41, 60, 61 The value of structured pharmacy minor ailment programs in the UK and Canada have 
enhanced the delivery of primary care services, promoted efficiencies and reduced overall health 
care costs. 55, 62, 63 
International MASs differ in their structural features, presentation and delivery. It is likely that 
structural design features affect the local and national usability and impact of the programs and 
influence access, outcomes, usability and overall costs. This is the first known international review 
that considers the key features of international community pharmacy-based MASs so as to identify 
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the key elements for consideration for their design. No records reported the evaluation of structural 
design or implementation of MASs; however, previous research has evaluated the success, uptake, 
and use of MASs. 50, 51, 64 Thus, there is a need to promote the development of a service model to 
promote effective service design and implementation into community pharmacy. Policymakers need 
to consider the importance of linking the theoretical service components to service planning and 
implementation strategies.  
The varied patient eligibility criteria affect the types of individuals accessing MASs. Whilst all UK-
based MASs are available to individuals who are exempt from NHS prescription charges, 65% of 
English MASs are accessible to individuals who do pay NHS prescription charges. NHS 
recommendations indicate that localities with high levels of income deprivation may benefit from a 
MAS as individuals cannot typically afford the costs associated with purchasing OTC medicines 
(acting as a barrier to the utilisation of community pharmacies and access to appropriate treatment), 
and consequently utilise GP services. 65 The availability of the MAS to individuals who do pay NHS 
prescription charges (in the UK) promotes equity of access to essential healthcare, not just 
exclusively to deprived population groups.  
Canadian MASs are accessible to all individuals in their respective province, independent of the level 
of deprivation or income, indicating the benefits in opening the service to the wider community. This 
increases access to primary care services and reduces the burden of minor ailment care on GP and 
A&E services. All individuals need to access self-care and minor ailment treatment at some point, 
and if not accessing these services in community pharmacies will utilise other primary care sites, 
such as GP and A&E services. Thus, enhancing access to a wider variety of individuals may be 
beneficial in reducing the overall health care burden and transferring minor ailment sufferers to 
community pharmacy. MASs give individuals greater choice in the source of care and the treating 
health care professional.  
Interestingly ,the MAS in Saskatchewan is available only to residents who have already self-
diagnosed their presenting minor ailment. A patient’s inability to self-diagnose their own minor 
ailment does not allow them access to the service. A potential reason for this “self-diagnosis 
principle” in the Saskatchewan guidelines is that GPs claim that pharmacists are unable to diagnose. 
66 Thus, suitable MAS users may potentially be diverted back to other sources of minor ailment care 
if unable to self-diagnose appropriately, thus potentially increasing pressures on other primary care 
sources.  
A significant proportion of MASs (82%) are accessible to patients who self-present to community 
pharmacies (not requiring a GP or GP Practice staff referral), promoting ease of access to individual 
consumers. Easy ‘walk-in’ access to the scheme recognises the role of the community pharmacy as a 
primary health care nexus and health destination where pharmacists can effectively treat and 
manage minor ailment symptoms. ‘Walk-in’ access allows pharmacies to operate the MAS 
independent of whether patients are registered with local GP surgeries, promoting greater MAS 
utilisation. Eighteen percent of MASs require patients to consult GP surgeries for a referral to the 
MAS. This referral may be by offering patients referral documentation (voucher/health passport 
documents) or by directly notifying the pharmacy. Whilst this provides direct evidence of whether 
the MAS consultation replaces the GP appointment, it also increases GP Practice staff’s workload as 
a triage point. Despite this, greater MAS utilisation was attributed to collaborative efforts with 
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GPs/practice staff facilitating referrals. 51 However, if individuals need to consult GP Practices to seek 
referrals, the need to visit MASs may be neglected if individuals are already at primary care provider 
sites who can offer necessary care. 
The privacy requirements indicated in all MASs highlights the confidential nature of the consultation, 
placing greater importance on the consultation rather than merely the provision of advice and/or 
supply of a product. The appropriate use of private consultation rooms offers many benefits in 
promoting MASs and improving the public perception of community pharmacists. Their use 
facilitates open communication between patients and pharmacists, and respects patient’s personal 
and privacy requirements. They allow community pharmacists to access patient information and 
make holistic, informed decisions. 67 Evidence indicates that the lack of privacy in some community 
pharmacies acts as a potential barrier to MAS consultations. 54 Furthermore, limited privacy is 
considered to be a barrier to pharmacy services. 68, 69  
MASs are pharmacist led clinical care services operated by or under the supervision of a registered 
community pharmacist, (with assistance from appropriately trained staff members). The delivery of 
MASs by pharmacists recognises the evolution of the pharmacist’s professional role, from primary 
dispensers and medication suppliers to incorporate the delivery of safe and effective use of medicine 
in a collaborative environment. Similarly, the inclusion of appropriately trained staff members in 
service guidelines highlights the importance of their support role in delivering the service and 
facilitating the delivery of care in community pharmacy. They play an essential role in the 
administration, maintenance, record keeping and patient interaction aspects of the service.  
The varied nature and scope of complexity of conditions treated under MASs indicate the depth of 
pharmacist skills, being able to offer self-care advice, appropriate referrals, or issue prescription 
products under PGDs in England, such as chloramphenicol 0.5% eye drops and trimethoprim tablets. 
In Alberta (Canada), pharmacists who have obtained ‘additional prescribing authority’ are licensed to 
prescribe medication in areas that they have demonstrated competency (with the exception of 
narcotics and controlled drugs). Access to a greater medicinal formulary allows pharmacists to 
optimise minor ailment care in the community. This is consistent with the findings of Pumtong et al., 
who reported that the limited formulary available to pharmacists acted as a barrier to patient care, 
and the restrictive nature of such formularies may result in more GP referrals to obtain a ‘better’ 
treatment option. 53   
Structured clinical training requirements exists for several MASs in the UK and Canada, yet very little 
or nil formal training is offered to other staff associated to the delivery and successful utilisation of 
MASs including GPs, GP Practice staff and receptionists, community pharmacy staff and other allied 
health care professionals. In order for other health care sites to triage individuals effectively, it is 
essential they have an understanding of local MASs, conditions treated and mode of operation. 
Evidence highlights the key role that GP practice staff and receptionists play with regards to 
promoting the MAS at GP surgeries and referring the appropriate patients to the service. 51 Similarly, 
Medicines Counter Assistants (MCAs) in England play a vital role MAS delivery. 60, 70 Ensuring that 
MCAs are trained in service delivery promotes utilisation and uptake of the service. Research 
indicates that health care providers (and the general public) may not have an understanding of 
MASs, the conditions treated and the treatment options available in community pharmacy. Thus, 
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promoting awareness and understanding of the MAS in the healthcare community is essential to 
promote the use of MASs. 71  
Pharmacists are largely required to practice within their own competency and skill area. Additional 
clinical training is required in nearly half of the international MASs, however a lack of training 
requirements across MASs may be indicative of pharmacists already being adequately qualified to 
manage and treat minor ailments from their own training. This is consistent with Lee 72 and Pumtong 
et al., 53 indicating that some pharmacists perceive that additional minor ailment training is 
unnecessary, having completed such training during their own studies and practical workplace 
experience. 53, 72 Registered community pharmacists already possess invaluable skills, having 
completed university-based training and clinical assessments. Minor ailment management is a core 
professional activity. In fact, the completion of additional clinical training for pharmacists may be a 
barrier to them obtaining accreditation to deliver the service. Thus, the value of training may lie in 
educating pharmacists regarding the operational elements of the MAS, use of protocols and 
communication with other healthcare providers. 
Interestingly, Canadian MASs required pharmacists to notify GP providers of the patient consultation 
and treatment plan. Yet, very few UK- based MASs were associated with structured communication 
pathways with other health care professionals (such as GPs). This differed to other pharmacy clinical 
services that entailed structured communication to GPs, such as Medicines Use Reviews or New 
Medicines Service (England). A potential reason for this may be that the need for structured 
communication between pharmacists and GPs may not be required for minor conditions that resolve 
spontaneously through the use of self-care, ie, the use of an oral antihistamine to treat hayfever. GP 
review of such minor ailment cases is a poor use of resources that could be diverted elsewhere. 
Nevertheless, the need for such communication pathways is necessary for conditions that do not 
resolve, or present with alarm symptoms or follow-up treatment and management that cannot be 
treated in the pharmacy. However, the value of reporting pharmacist based interventions to GPs 
through structured pathways highlights that GPs are at the centre of primary care.  Greater 
collaborative efforts between GPs and pharmacists offer more effective patient services. 73 Evidence 
suggests that the professional relationships between GPs and pharmacists improved as a result of 
offering the MAS service. 51 Furthermore, literature suggests that collaboration, communication and 
teamwork are vital to provide essential and effective healthcare. 48  
The majority of MASs offer reimbursement independent of the outcome of the consultation. The 
varied pharmacy remuneration models highlight the role of community pharmacies as the primary 
source of medicines (as opposed to supermarkets or other sites). Most remuneration models are 
designed around patients receiving a product to treat minor ailments with 94% of English MASs 
being remunerated for a consultation fee and product cost. This is in line with international 
literature that suggests that the majority of countries offer remuneration for pharmacy-based 
services only when a medicine is paid under the reimbursement arrangements. 74 This payment 
method allows community pharmacists to be remunerated based on the number of MASs delivered. 
There is a stronger incentive to deliver more services, and actively promote self-care and transfer 
minor ailment care to MASs. A possible disadvantage associated with this remuneration method is 
that as pharmacists seek greater volumes of patients consulting MASs, opportunities for potential 
misuse of MASs may occur.  
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In Saskatchewan (Canada), the $18 CAD remuneration fee is only offered for minor ailments that 
result in a prescription. A concern associated with remunerating pharmacies only if drug treatment is 
given may be that pharmacists are motivated to prescribe products when unnecessary or where 
alternative treatment options, such as self-care are available. Additionally, pharmacists’ skills may 
not be fully utilised and recognised, 72 and thus community pharmacists’ skills may be underutilised.  
The capitation remuneration model is a pre-determined population-centred method of calculation, 
determined by a fixed number of patients being enrolled at a community pharmacy. It requires 
patients to be affiliated to a community pharmacy.  This payment model allows community 
pharmacists to treat patients in a manner that is not influenced by the cost of drug treatment. It also 
may encourage pharmacists to promote treatment with non-drug measures. The use of this model 
was the least commonly used payment system across MASs. Whilst it appears that patients are 
mobile across community pharmacies, it may not be reflective of MAS utilisation and uptake. 
Additionally, as this method of payment is determined by a defined population, pharmacists may 
encourage people to access MASs that do not require the service.   
Each remuneration model presents its own benefits and challenges, MAS providers need to be fairly 
remunerated by service commissioners to ensure the healthcare needs of users are met efficiently, 
and that pharmacists can allocate time and resources to service delivery. However, a structured 
remuneration program could ensure a commitment to the quality of the service and potential to 
expand, differentiate, or diversify service provision. 
Limitations 
The aim of this review was to offer an international perspective regarding MASs for global 
policymakers to consider implementation. Consequently, no geographical restrictions were imposed 
during the literature search; however, the majority of the records identified were from the UK 
(particularly England). This limited the international outlook of the research as UK based MASs were 
tailored for their local or national healthcare systems and policies. Furthermore, the lack of available 
data relating to the structural features of identified MAS’s limited the scope of analysis (particularly 
Canadian services). 
The nature of literature searching and retrieval presented some challenges and may have introduced 
bias into search results. Search engines were more likely to display the preferred records within 
certain geographical locations, determined by the automatic relevance rating. Additionally, some 
searches within the search engines used displayed a smaller number (than ten pages) as potential 
records for screening.  Furthermore, the evolving and transient nature of the internet and changing 
website domains and URLs influenced the records identified and later accessed during the grey 
literature searching process.  
Future research 
The utilisation and uptake of MASs at an international level is indicative of the potential for the 
expansion of primary health care services by community pharmacy. Previous evidence including 
Paudyal et. al, 50 Watson et. al, 62  and the Mary Seacole Research Institute 51 reported local or 
national outcomes of MASs. No publications considered the role of MAS implementation and service 
design in achieving service outcomes despite its fundamental importance. Furthermore, most of the 
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published evaluation reports were UK based. Further research should consider other international 
MASs and enhanced self-care services.  
Further studies should consider minor ailment management in different settings, including 
pharmacies, A&E departments and other primary care services and their implementation processes. 
The cost of minor ailment care should be considered broadly, from the patient, provider and 
government perspectives, beyond the cost of the consultation and treatment, and should consider 
time spent by patient/health care provider seeking treatment, time to access treatment, 
convenience, and availability of parking at treatment site, loss of productivity, cost of re-
consultation, and impact on other resources and quality of life etc.  
Further research is necessary to facilitate changes in health policy, including clinical and economic 
evaluations and implementation research. Potential expansion and legislative changes to promote 
implementation of MAS and community pharmacy based self-care may be a feature of more 
extensive, complete economic and clinical evaluations of MASs.  However, the utilisation and uptake 
of MASs at an international level is indicative of its potential value. The Birmingham (UK) MAS 
delivered cost savings of £2 million in 2014. 64 A modelling analysis considering the implementation 
of a national MAS in England is predicted to generate cost savings of £12 to £56 million. 63, 75 Existing 
MAS providers should consider the effectiveness and outcomes of MASs alongside the design model 
to promote community pharmacy as the preferred treatment site for minor ailment care. 
Conclusion 
It is evident that MASs are unique in their structural design parameters. These parameters need to 
be adapted to the local health context, population and stakeholder needs and health systems. The 
impact of these design features and structural features need to be assessed when considering MAS 
outcomes and success. The implementation of a MAS is a multi-stage, collaborative process with 
significant stakeholder impacts. Effective service implementation requires the combined skillset of 
multiple stakeholders to ensure robust frameworks, protocols, and governance structures.  
Existing research indicates that MASs have significant benefits to patients, health care professionals, 
and governments to transfer minor ailment treatment to community pharmacy. It would allow 
greater volumes of people to access appropriate care in a timely, efficient manner without 
increasing the strain on existing resources. Better utilisation of community pharmacies and 
pharmacists, in conjunction with GPs at the core of the primary care system is efficient and 
implementable to meet essential primary care needs and improve access to health care services. 
Thus, the use of the proposed MAS model is essential to promote the ongoing sustainability of the 
services and the potential to scale them up. 
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“Minor ailments scheme” 
“Minor ailments service” 
“Minor illness service” 
“Minor ailments assessment” 
“Minor ailment prescribing” 
“Minor ailment service providers” 
“Minor ailments scheme England” 
“Minor ailments scheme Scotland” 
“Minor ailments scheme Wales” 
“Minor ailments scheme Northern Ireland” 
“Minor ailments scheme Canada” 
“Minor ailment prescribing Canada” 
“Minor ailments assessment Canada”  
“Minor ailment prescribing United States of America” 
 
  
Table 1. Search Strategy Used for Literature Retrieval 
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Figure 2. Proposed Service Design Model. 
• This includes active communication with GPs, pharmacists, other allied 
health practitioners, professional organisations, policy makers and service 
users.
Stakeholder engagement
• Elements of service design that need to be considered include:
• Aims and objectives
• Patient eligibility and access methods
• Cost of access
• Service flow and patient experience
• Location of delivery
• Minor ailments treated and drug formulary
• Protocols and algorithms
• Patient outcomes and follow up 
• Record keeping and use of technology
• Professional collaboration and communication
• Staff training and reimbursement
• Marketing and communication
Service planning and design
• A specific, clear governance structure to outline the policies and procedures 
aligned to service aims and objectives
Establishing a governance structure
• Pilot MAS implementation considerate of barriers, facilitators and other 
managment strategies
Implementation
• Regular audit and evaluationof existing service model in light of key 
performance indicators
• Strengthening existing engagement and governance strategies
• Adopting service revisions
Monitoring, review and evaluation
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Figure 1 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Customised search 
engines 
 n= 280 
 
Records screened and 
duplicates removed  
n= 717 
Targeted web based 
searches 
 n= 1630 records 
Consultation with 
experts 
 n= 66 contacted 
Full text records 
assessed for eligibility 
 n= 698 
   
Records included in 
qualitative synthesis   
n= 147 
Full text records excluded 
with reasons n= 551 
Duplicate records (n=5) 
Published by independent authors 
(n= 4) 
Draft document (n= 3) 
Did not include a community 
pharmacy- based MAS (n= 71) 
Did not include standards for 
implementation of MAS (n= 476) 
* Records could be excluded 
for more than one criterion 
Records excluded 
 n= 19 
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Highlights 
 
• This is the first known comparative review of minor ailments service features. 
• A minor ailments service design model is proposed. 
• Service delivery needs to be adapted to the local context to promote success and 
viability. 
• Utilisation of a design model requires implementation and change management 
theories. 
 
